Studies in Dermatology, LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$19,094	3
2024	Research	$14,908	2
2023	Research	$2,535	1
2022	Research	$9,332	2
2021	Research	$248,446	3
2020	Research	$34,502	1

Breakdown

Who paid Research payments · program years 2020–2025

Eli Lilly and Company $171,297 6 payments
Amgen Inc. $140,664 2 payments
E.R. Squibb & Sons, L.L.C. $16,857 4 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis $158,325 4 payments
ABP 654 P3 PsO Study $106,161 1 payment
ABP 654 Phase 3 PsO Study $34,502 1 payment
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) $12,000 1 payment
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis $7,768 1 payment
Observation Priority E Short - Lebrikizumab - Atopic Dermatitis $5,204 1 payment
A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUTING IMPACT OF DEUCRAVACITINIB ON QoL, EFFICACY AND SAFETY IN PATIENTS WITH PLAQUE PSORIASIS AND IMPAIRED HEALTH-RELATED QUALITY OF LIFE $2,967 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting $1,890 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.